Skip to main content

Table 2 Pathological complete response and minimal residual disease in response to D-FEC and Bev + D-FEC – ARTemis trial

From: Neoadjuvant trials in early breast cancer: pathological response at surgery and correlation to longer term outcomes – what does it all mean?

  D → FEC Bev + D → FEC  
  % (95 % CI) % (95 % CI) p valuea
pCR in all breast tumours and absence of disease in all removed axillary lymph nodes (ypT0/Tis ypN0)b (n = 66/393) (n = 87/388) 0.03
17 % (13–21 %) 22 % (18–27 %)
ER negative (Allred 0–2) (n = 241) 31 % (23–40) 45 % (36–55)  
ER weakly positive (Allred 3–5) (n = 74) 30 % (16–47) 51 % (34–68)  
ER strongly positive (Allred 6–8) (n = 466) 7 % (4–11) 6 % (3–10)  
pCR in all breast tumours (ypT0/Tis) (n = 76/394) (n = 99/388) 0.02
19 % (16–24) 26 % (21–30)
ER negative (Allred 0–2) (n = 241) 34 % (25–43) 49 % (39–58)  
ER weakly positive (Allred 3–5) (n = 75) 39 % (24–57) 59 % (42–75)  
ER strongly positive (Allred 6–8) (n = 466) 9 % (5–13) 8 % (5–12)  
pCR or minimal residual disease in all breast tumours (n = 114/394) (n = 138/388) 0.03
29 % (25–34 %) 36 % (31–41 %)
ER negative (Allred 0–2) (n = 241) 44 % (35–54) 58 % (49–67)  
ER weakly positive (Allred 3–5) (n = 75) 50 % (33–67) 70 % (53–84)  
ER strongly positive (Allred 6–8) (n = 466) 18 % (13–23) 19 % (14–24)  
  1. aAdjusted for the five stratification variables (age [≤50, >50 years old], ER status [negative, weakly positive, strongly positive], tumour size [≤50, >50 mm], clinical involvement of axillary nodes [no, yes], and inflammatory or locally advanced disease [no, yes])
  2. bPrimary endpoint for the ARTemis trial